# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **SCHEDULE 13D**

Under the Securities Exchange Act of 1934 (Amendment No. 4)\*

# Gamida Cell Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities)

M47364100 (CUSIP Number)

Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Street, 28th Floor New York, New York 10019 (212) 247-6400

with copies to:

Nicholas P. Pellicani Debevoise & Plimpton LLP 919 Third Avenue New York, New York 10022 (212) 909-6000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 $\begin{array}{c} \textbf{June 9, 2022} \\ \textbf{(Date of Event which Requires Filing of this Statement)} \end{array}$ 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  $\Box$ 

1	NAME OF I	DEDO	DTING DEDGON		
1	NAME OF REPORTING PERSON.				
	AI Gamida Holdings LLC				
2			PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)		
		b) 🗆			
3	SEC USE O	NLY			
4	SOURCE O	F FUN	NDS (SEE INSTRUCTIONS)		
	AF				
5		DISCI	LOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		
3	CHECKILI	J15C1	SOSORE OF ELONE PROCEEDINGS IS REQUIRED FORSONIVE TO TIEMS 2(u) of 2(c)		
6	CITIZENSH	IIP OF	R PLACE OF ORGANIZATION		
	State of Dela				
		7	SOLE VOTING POWER		
N	UMBER OF		3,750,000 shares		
- 11	SHARES	8	SHARED VOTING POWER		
BE	BENEFICIALLY		SHARED VOTINGTOWER		
O	OWNED BY		0 shares		
D	EACH REPORTING		SOLE DISPOSITIVE POWER		
	PERSON				
	WITH		3,750,000 shares		
			SHARED DISPOSITIVE POWER		
			O shores		
11	AGGREGAT	LE VI	0 shares 40UNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
11	AUUKEUA	LEAN	MOONT BENEFICIALLY OWNED BY EACH REFORTING FERSON		
	3,750,000 sh	ares			
12			AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
	$\boxtimes$ (1)				
13	PERCENT (	OF CL	ASS REPRESENTED BY AMOUNT IN ROW (11)		
	6.26%(2)				
14		ED∩D	TING DEDSON (SEE INSTRICTIONS)		
14	4 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)				
	OO (Limited Liability Company)				

- (1) Excludes 3,071,239 Ordinary Shares that are beneficially owned by Clal Biotechnology Industries Ltd. and its subsidiaries and 3,111,111 Ordinary Shares that are directly owned by AI Biotechnology LLC.
- (2) All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement are based on 59,946,298 Ordinary Shares issued and outstanding on May 9, 2022, as reported in the Issuer's Form 10-Q filed with the SEC on May 12, 2022.

1	NAME OF REPORTING PERSON.				
	Access Industries Holdings LLC				
2		E API	PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)		
3	SEC USE O	NLY			
4	SOURCE O	F FUN	NDS (SEE INSTRUCTIONS)		
	AF				
5	CHECK IF I	DISCI	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		
6	CITIZENSH	IP OF	R PLACE OF ORGANIZATION		
	State of Dela	ware			
		7	SOLE VOTING POWER		
N	UMBER OF		0 shares		
BE	SHARES NEFICIALLY	8	SHARED VOTING POWER		
O	OWNED BY EACH		6,182,350 shares		
	EPORTING	9	SOLE DISPOSITIVE POWER		
	PERSON WITH		0 shares		
			SHARED DISPOSITIVE POWER		
			6,182,350 shares		
11	AGGREGAT	E AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	6,182,350 sh				
12	CHECK IF	THE A	AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
12	$\boxtimes$ (1)				
13	PERCENT (	JF CL	ASS REPRESENTED BY AMOUNT IN ROW (11)		
1.4	10.31%(2)	EDOR	TING BERGON (GET INGTRICATIONS)		
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)				
	OO (Limited Liability Company)				

- (1)
- Excludes 3,750,000 Ordinary Shares that are owned directly by AI Gamida Holdings LLC. All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement are based on 59,946,298 Ordinary Shares issued and outstanding on May 9, 2022, as reported in the Issuer's Form 10-Q filed with the SEC on May 12, 2022. (2)

1	NAME OF REPORTING PERSON.				
	Access Industries, LLC				
2					
	(a) □ (t	o) 🗆			
3	SEC USE O	NIV			
J	SEC OSE O	NL1			
4	SOURCE O	F FUN	NDS (SEE INSTRUCTIONS)		
	AF				
5		DISCI	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		
	CILCUL II	31001	2(4) (12(4)		
6	CITIZENSH	IP OF	R PLACE OF ORGANIZATION		
	State of Dela	ware			
	State of Dela	7	SOLE VOTING POWER		
		,			
N	UMBER OF		0 shares		
BE	SHARES NEFICIALLY	8	SHARED VOTING POWER		
	WNED BY		6,182,350 shares		
	EACH	9	SOLE DISPOSITIVE POWER		
	EPORTING PERSON		SOLL DISTOSTITULE OF THE R		
	PERSON WITH		0 shares		
	***************************************		SHARED DISPOSITIVE POWER		
			6,182,350 shares		
11	AGGREGAT	E AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
10	6,182,350 shares				
12	2 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
	$\boxtimes$ (1)				
13					
1.4	10.31%(2)	EDOE	TIME DEDCOM (SEE DISTRICTIONS)		
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)				
	OO (Limited Liability Company)				

- (1)
- Excludes 3,750,000 Ordinary Shares that are owned directly by AI Gamida Holdings LLC. All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement are based on 59,946,298 Ordinary Shares issued and outstanding on May 9, 2022, as reported in the Issuer's Form 10-Q filed with the SEC on May 12, 2022. (2)

1	NAME OF REPORTING PERSON.				
	Access Industries Management, LLC				
2			PROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)		
	(a) □ (l	b) [			
3	SEC USE O	NIT X7			
3	SEC USE O	NLI			
4	SOURCEO	E ELIN	IDS (SEE INSTRUCTIONS)		
7	SOURCE OF	1 1 01	(DEL INSTRUCTIONS)		
	AF				
5		DISCI	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		
6	CITIZENSH	IP OF	R PLACE OF ORGANIZATION		
	State of Dela				
		7	SOLE VOTING POWER		
N	UMBER OF		0 shares		
	SHARES	8	SHARED VOTING POWER		
BE	NEFICIALLY	0	SIRRED VOINGTOWER		
C	WNED BY		9,932,350 shares		
D	EACH EPORTING	9	SOLE DISPOSITIVE POWER		
K	PERSON				
	WITH		0 shares		
	***************************************		SHARED DISPOSITIVE POWER		
44	9,932,350 shares				
11	AGGREGA	E AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	9,932,350 sh	arec			
12			GGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
	CHECKI	· · · ·	desired in Entropy (ii) Encloses certain on the (obe in on the entropy		
13	PERCENT (	OF CL	ASS REPRESENTED BY AMOUNT IN ROW (11)		
	16.57%(1)				
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)				
	OO (I imited Liebility Commons)				
	OO (Limited Liability Company)				

(1) All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement are based on 59,946,298 Ordinary Shares issued and outstanding on May 9, 2022, as reported in the Issuer's Form 10-Q filed with the SEC on May 12, 2022.

1	NAME OF I	REPO	RTING PERSON.		
	Clal Biotechnology Industries Ltd.				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(a) □ (t	o) 🗆			
3	SEC USE O	NI V			
3	SEC OSE O	INL I			
4	SOURCE O	F FUN	NDS (SEE INSTRUCTIONS)		
	WC				
5		DISCI	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		
6		IP OF	R PLACE OF ORGANIZATION		
	Israel				
	isiaci	7	SOLE VOTING POWER		
N	UMBER OF				
IN	SHARES	8	1,696,862 shares SHARED VOTING POWER		
	BENEFICIALLY		SHARED VOTINGTOWER		
C	OWNED BY EACH		1,374,377 shares		
	EPORTING	9	SOLE DISPOSITIVE POWER		
	PERSON WITH		1,696,862 shares		
	WIII		SHARED DISPOSITIVE POWER		
			1,374,377 shares		
11	AGGREGAT	TE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	3,071,239 sh	ares			
12			AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
	$\boxtimes$ (1)				
13	_··				
	5 100/(3)				
14	5.12%(2) TYPE OF R	EPOR	TING PERSON (SEE INSTRUCTIONS)		
- '					
	CO				

- Excludes 3,750,000 Ordinary Shares that are owned directly by AI Gamida Holdings LLC and 3,111,111 Ordinary Shares that are owned directly
- by AI Biotechnology LLC.
  All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement are based on 59,946,298 Ordinary Shares issued and outstanding on May 9, 2022, as reported in the Issuer's Form 10-Q filed with the SEC on May 12, 2022. (2)

1	NAME OF I	REPO	RTING PERSON.	
2	Bio Medical Investment (1997) Ltd.  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
_		o) 🗆	ROTALITE BOTT IT TIMENIBER OF IT GROOT (GEE IT GITGO TIOT (G)	
3	SEC USE O	NLY		
4	SOURCE O	F FUN	NDS (SEE INSTRUCTIONS)	
	WC			
5		DISCI	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)	
6		IP OF	R PLACE OF ORGANIZATION	
	Israel			
	131401	7	SOLE VOTING POWER	
N	UMBER OF			
11	SHARES	8	1,374,377 shares SHARED VOTING POWER	
	BENEFICIALLY		SIRKED VOINGTOWER	
C	OWNED BY EACH		0 shares	
R	REPORTING		SOLE DISPOSITIVE POWER	
	PERSON		1,374,377 shares	
	WITH		SHARED DISPOSITIVE POWER	
			0 shares	
11	AGGREGAT	TE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,374,377 sh	orca		
12			AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
			(., 2.10.00)	
	$\boxtimes$ (1)			
13	PERCENT (	)F CL	ASS REPRESENTED BY AMOUNT IN ROW (11)	
	2.29%(2)			
14	TYPE OF R	EPOR	TING PERSON (SEE INSTRUCTIONS)	
	CO			

- (1) Excludes 1,696,862 Ordinary Shares that are beneficially owned by Clal Biotechnology Industries Ltd., 3,750,000 Ordinary Shares that are owned directly by AI Gamida Holdings LLC and 3,111,111 Ordinary Shares that are owned directly by AI Biotechnology LLC.
- (2) All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement are based on 59,946,298 Ordinary Shares issued and outstanding on May 9, 2022, as reported in the Issuer's Form 10-Q filed with the SEC on May 12, 2022.

1	NAME OF REPORTING PERSON.				
	Len Blavatnik				
2					
	(a) □ (t	o) 🗆			
3	SEC USE O	NLY			
J	520 052 0				
4	SOURCE O	F FUN	IDS (SEE INSTRUCTIONS)		
	AF				
5		DISCI	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		
	_				
	CITIZENGU	ID OF	R PLACE OF ORGANIZATION		
6	CHIZENSH	IP OF	A PLACE OF ORGANIZATION		
	United State	s of A	merica		
		7	SOLE VOTING POWER		
N	UMBER OF		0 shares		
	SHARES	8	SHARED VOTING POWER		
	NEFICIALLY				
O	OWNED BY EACH		9,932,350 shares		
R	EPORTING	9	SOLE DISPOSITIVE POWER		
PERSON			0 shares		
	WITH		SHARED DISPOSITIVE POWER		
			0.022.250.1		
11	AGGREGAT	TE AN	9,932,350 shares MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
• •	ridditEdri	L I III	TOOM BENEFICIALLY OWNED BY EACH REFORMING LEASON		
	9,932,350 sh				
12	CHECK IF	THE A	AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
13	<u> </u>				
	16 570/(1)				
14	16.57%(1)	EPOR	TING PERSON (SEE INSTRUCTIONS)		
- '	THE OF REPORTING PERSON (SEE INSTRUCTIONS)				
	IN				

(1) All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement are based on 59,946,298 Ordinary Shares issued and outstanding on May 9, 2022, as reported in the Issuer's Form 10-Q filed with the SEC on May 12, 2022.

1	NAME OF I	REPO	RTING PERSON.	
	ALD'academia LLC			
2	AI Biotechnology LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
		b) [		
2	and tian of			
3	SEC USE O	NLY		
4	SOURCE O	F FUN	NDS (SEE INSTRUCTIONS)	
	AF			
5		DISCI	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)	
6		IIP OF	R PLACE OF ORGANIZATION	
	State of Dela			
	State of Dela	ware 7	SOLE VOTING POWER	
		,		
N	UMBER OF SHARES	_	3,111,111 shares	
BE	NEFICIALLY	8	SHARED VOTING POWER	
O	WNED BY		0 shares	
R	EACH EPORTING	9	SOLE DISPOSITIVE POWER	
	PERSON		3,111,111 shares	
	WITH		SHARED DISPOSITIVE POWER	
0 shares		V W		
11	AGGREGA	TE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	3,111,111 sh	ares		
12	CHECK IF	ГНЕ А	AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
	$\boxtimes(1)$			
13		OF CL	ASS REPRESENTED BY AMOUNT IN ROW (11)	
	5 100/(2)			
14	5.19%(2) TYPE OF R	FPOR	TING PERSON (SEE INSTRUCTIONS)	
17	111 L OF REFORMING LERSON (SEE INSTRUCTIONS)			
	OO (Limited Liability Company)			

- (1) Excludes 3,071,239 Ordinary Shares that are beneficially owned by Clal Biotechnology Industries Ltd. and its subsidiaries and 3,750,000 Ordinary Shares that are owned directly by AI Gamida Holdings LLC.
- (2) All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement are based on 59,946,298 Ordinary Shares issued and outstanding on May 9, 2022, as reported in the Issuer's Form 10-Q filed with the SEC on May 12, 2022.

#### CONTINUATION PAGES TO AMENDMENT NO. 4 TO SCHEDULE 13D

This Amendment No. 4 to Schedule 13D is being filed by AI Gamida Holdings LLC ("AI Gamida"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM"), Access Industries, LLC ("Access LLC"), Bio Medical Investment (1997) Ltd. ("Bio Medical"), Clal Biotechnology Industries Ltd. ("CBI") and Len Blavatnik (collectively, the "Original Reporting Persons") and AI Biotechnology LLC ("AIB" and, together with the Original Reporting Persons, the "Reporting Persons", and each, a "Reporting Person") to report certain changes in beneficial ownership of ordinary shares, par value NIS 0.01 per share (the "Ordinary Shares"), of Gamida Cell Ltd. (the "Issuer") held by the Reporting Persons.

The Schedule 13D filed by the Original Reporting Persons with the Securities and Exchange Commission (the "SEC") on November 9, 2018, as amended and supplemented by Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on July 3, 2019, Amendment No. 2 to the Schedule 13D filed by the Reporting Persons with the SEC on May 22, 2020 and Amendment No. 3 to the Schedule 13D filed by the Reporting Persons with the SEC on February 8, 2022 (together, the "Schedule"), is hereby amended and supplemented by the Reporting Persons as set forth below in this Amendment No. 4. This amendment is filed by the Reporting Persons in accordance with Rule 13d-2 of the Securities Exchange Act of 1934, as amended, and refers only to information that has materially changed since the filing of the Schedule. The items identified below, or the particular paragraphs of such items which are identified below, are amended as set forth below. Unless otherwise indicated, all capitalized terms used and not defined herein have the respective meanings assigned to them in the Schedule.

#### Item 4 Purpose of Transaction

The disclosure in Item 4 to the Schedule is hereby supplemented by adding the following at the end thereof:

Ofer Gonen resigned from the Issuer's board of directors on June 9, 2022, in connection with his appointment as Chief Executive Officer of MediWound Ltd., effective July 1, 2022, and his expected resignation as Chief Executive Officer of CBI.

#### Item 5 Interest in Securities of the Issuer

Item 5 to the Schedule is hereby amended and restated as follows:

(a) and (b) The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of common stock (including but not limited to footnotes to such information) are incorporated herein by reference

The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of common stock as to which each of the persons or entities referenced in Item 2 above has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited to footnotes to such information) are incorporated herein by reference.

3,750,000 Ordinary Shares are owned directly by AI Gamida and may be deemed to be beneficially owned by AIM and Len Blavatnik because (i) AIM and Len Blavatnik control AI Gamida, and (ii) Len Blavatnik controls AIM. Each of the Reporting Persons (other than AI Gamida), and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of the securities held directly by AI Gamida.

3,071,239 Ordinary Shares may be deemed to be beneficially owned by CBI, including (i) 1,509,369 Ordinary Shares owned directly by CBI, (ii) 160,743 Ordinary Shares issuable upon exercise of warrants owned directly by CBI, (iii) options to purchase 10,000 Ordinary Shares owned directly by CBI, with an exercise price of \$4.70 per share, which are currently exercisable, (iv) options to purchase 12,000 Ordinary Shares owned directly by CBI, with an exercise price of \$6.66 per share, which are currently exercisable, (v) options to purchase 4,750 Ordinary Shares owned directly by CBI, with an exercise price of \$2.63 per share, which are currently exercisable and (vi) 1,374,377 Ordinary Shares owned directly by Bio Medical, which is a wholly owned subsidiary of CBI. CBI may be deemed to share voting and investment power over the shares held directly by Bio Medical because it controls that entity. CBI is a publicly traded company traded on the Tel Aviv Stock Exchange.

1,374,377 Ordinary Shares are owned directly by Bio Medical, which is a wholly owned subsidiary of CBI.

3,111,111 Ordinary Shares are owned directly by AIB, which is a wholly owned subsidiary of AIH.

Each of AIH, Access LLC, AIM and Mr. Blavatnik may be deemed to share voting and investment power over the Ordinary Shares deemed to be beneficially owned by CBI (including the shares held directly by Bio Medical) and the Ordinary Shares owned directly by AIB because (i) Len Blavatnik controls AIM, AIH, Access LLC and AI International GP Limited (the general partner of AI SMS, as defined below), (ii) Access LLC controls a majority of the outstanding voting interests in AIH, (iii) AIM controls Access LLC and AIH, (iv) AIH owns AIB, (v) AIH owns a majority of the equity of AI SMS L.P. ("AI SMS"), (vi) AI SMS owns a majority of the equity of AI Diversified Holdings Ltd. ("Holdings Limited"), (vii) Holdings Limited owns AI Diversified Parent S.à r.l., which owns AI Diversified Holdings S.à r.l., which owns Access AI Ltd ("Access AI"), (viii) Access AI wholly owns Clal Industries Ltd. ("CI"), and (ix) CI is the controlling shareholder of CBI. Each of the Reporting Persons (other than, (x) solely with respect to the securities held directly by CBI, CBI, (y) solely with respect to the securities held directly by AIB, AIB), and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of the securities held directly by CBI, Bio Medical and AIB.

- (c) Not applicable.
- (d) Not applicable.
- (e) Not applicable.

#### Item 7 Materials to Be Filed as Exhibits

**Exhibit** Description

99.9 Joint Filing Agreement, dated as of June 10, 2022.

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: June 10, 2022

AI GAMIDA HOLDINGS LLC By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

ACCESS INDUSTRIES HOLDINGS LLC By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

ACCESS INDUSTRIES MANAGEMENT, LLC /s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

ACCESS INDUSTRIES, LLC By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

CLAL BIOTECHNOLOGY INDUSTRIES LTD. /s/ Ofer Gonen

Name: Ofer Gonen

Title: Chief Executive Officer

/s/ Assaf Segal

Name: Assaf Segal

Title: Chief Financial Officer

BIO MEDICAL INVESTMENT (1997) LTD. /s/ Ofer Gonen

Name: Ofer Gonen Title: Director

/s/ Assaf Segal

Name: Assaf Segal Title: Director

AI BIOTECHNOLOGY LLC By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

\*

Name: Len Blavatnik

By: /s/ Alejandro Moreno

Name: Alejandro Moreno Attorney-in-Fact

<sup>\*</sup> The undersigned, by signing his name hereto, executes this Amendment No. 4 to Schedule 13D pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

#### Joint Filing Agreement

The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

In accordance with Rule 13d-1(k)(1) promulgated under the Securities and Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (and any amendments thereto) with respect to the Ordinary Shares, par value NIS 0.01 per share, beneficially owned by each of them, of Gamida Cell Ltd., an Israeli corporation. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13D.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 10th day of June, 2022.

By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

ACCESS INDUSTRIES HOLDINGS LLC By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

ACCESS INDUSTRIES MANAGEMENT, LLC /s/ Alejandro Moreno

AI GAMIDA HOLDINGS LLC

Name: Alejandro Moreno Title: Executive Vice President

ACCESS INDUSTRIES, LLC By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

CLAL BIOTECHNOLOGY INDUSTRIES LTD. /s/ Ofer Gonen

Name: Ofer Gonen

Title: Chief Executive Officer

/s/ Assaf Segal

Name: Assaf Segal

Title: Chief Financial Officer

BIO MEDICAL INVESTMENT (1997) LTD. /s/ Ofer Gonen

Name: Ofer Gonen Title: Director

/s/ Assaf Segal

Name: Assaf Segal Title: Director

AI BIOTECHNOLOGY LLC By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno Title: Executive Vice President

\*

Name: Len Blavatnik

By: /s/ Alejandro Moreno

Name: Alejandro Moreno Attorney-in-Fact

<sup>\*</sup> The undersigned, by signing his name hereto, executes this Joint Filing Agreement pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.